Kymera Therapeutics is approaching a high-stakes clinical milestone for KT-621 in eczema, with investors and analysts watching for data that could determine whether the program can compete in immunology after Dupixent’s dominance. The company is planning to announce results from a mid-stage trial before year-end, and analysts characterize the upcoming readout as among the most impactful immunology and inflammation updates of the year.